FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:626-631 March 1, 2001 Number 9 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Low-molecular-weight heparins are frequently used to treat venous thromboembolism, but optimal dosing regimens and clinical outcomes need further definition.

Methods In this multicenter, open-label study with blinded adjudication of end points, we randomly assigned patients with acute deep-vein thrombosis to one of three treatment regimens: intravenous administration of unfractionated heparin; subcutaneous administration of a low-molecular-weight heparin, reviparin, twice a day for one week; or subcutaneous administration of reviparin once a day for four weeks. The primary end point was evidence of regression of the thrombus on venography on day 21; secondary end points were recurrent venous thromboembolism, major bleeding within 90 days after enrollment, and death.

Results Of the patients receiving unfractionated heparin, 40.2 percent (129 of 321) had thrombus regression, as compared with 53.4 percent (175 of 328) of the patients receiving reviparin twice daily and 53.5 percent (167 of 312) of the patients receiving reviparin once daily. With regard to thrombus regression, reviparin administered twice daily was significantly more effective than unfractionated heparin (relative likelihood of thrombus regression, 1.28; 97.5 percent confidence interval, 1.08 to 1.52), as was reviparin administered once daily (relative likelihood, 1.29; 97.5 percent confidence interval, 1.08 to 1.53). Mortality and the frequency of episodes of major bleeding were similar in the three groups.

Conclusions In acute deep-vein thrombosis, reviparin regimens are more effective than unfractionated heparin in reducing the size of the thrombus. Reviparin is also more effective than unfractionated heparin for the prevention of recurrent thromboembolism and equally safe.

Source Information

From the International Institute of Thrombosis and Vascular Diseases, Frankfurt, Germany.

Address reprint requests to Dr. Breddin at the International Institute of Thrombosis and Vascular Diseases, Ferdinand-Schrey-Weg 6, D-60598 Frankfurt, Germany, or at breddin{at}em.uni-frankfurt.de.

Full Text of this Article

This article has been cited by other articles:

• Schulman, S., Beyth, R. J., Kearon, C., Levine, M. N. (2008). Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 257S-298S [Abstract] [Full Text]  
• Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., Comerota, A. J. (2008). Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 454S-545S [Abstract] [Full Text]  
• Warkentin, T. E., Greinacher, A. (2007). So, Does Low-Molecular-Weight Heparin Cause Less Heparin-Induced Thrombocytopenia Than Unfractionated Heparin or Not?. Chest 132: 1108-1110 [Full Text]  
• Morris, T. A., Castrejon, S., Devendra, G., Gamst, A. C. (2007). No Difference in Risk for Thrombocytopenia During Treatment of Pulmonary Embolism and Deep Venous Thrombosis With Either Low-Molecular-Weight Heparin or Unfractionated Heparin: A Metaanalysis. Chest 132: 1131-1139 [Abstract] [Full Text]  
• Agnelli, G., Gallus, A., Goldhaber, S. Z., Haas, S., Huisman, M. V., Hull, R. D., Kakkar, A. K., Misselwitz, F., Schellong, S., for the ODIXa-DVT Study Investigators, (2007). Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study. Circulation 116: 180-187 [Abstract] [Full Text]  
• The CREATE Trial Group Investigators*, (2005). Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation. JAMA 293: 427-435 [Abstract] [Full Text]  
• Hirsh, J., Raschke, R. (2004). Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 188S-203S [Abstract] [Full Text]  
• Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., Schulman, S. (2004). Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 287S-310S [Abstract] [Full Text]  
• McRae, S. J., Ginsberg, J. S. (2004). Initial Treatment of Venous Thromboembolism. Circulation 110: I-3-I-9 [Abstract] [Full Text]  
• Augustinos, P., Ouriel, K. (2004). Invasive Approaches to Treatment of Venous Thromboembolism. Circulation 110: I-27-I-34 [Abstract] [Full Text]  
• Elting, L. S., Escalante, C. P., Cooksley, C., Avritscher, E. B. C., Kurtin, D., Hamblin, L., Khosla, S. G., Rivera, E. (2004). Outcomes and Cost of Deep Venous Thrombosis Among Patients With Cancer. Arch Intern Med 164: 1653-1661 [Abstract] [Full Text]  
• Buller, H. R., Davidson, B. L., Decousus, H., Gallus, A., Gent, M., Piovella, F., Prins, M. H., Raskob, G., Segers, A. E.M., Cariou, R., Leeuwenkamp, O., Lensing, A. W.A., The Matisse Investigators*, (2004). Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis: A Randomized Trial. ANN INTERN MED 140: 867-873 [Abstract] [Full Text]  
• Writing Committee for the Galilei Investigators, (2004). Subcutaneous Adjusted-Dose Unfractionated Heparin vs Fixed-Dose Low-Molecular-Weight Heparin in the Initial Treatment of Venous Thromboembolism. Arch Intern Med 164: 1077-1083 [Abstract] [Full Text]  
• Quinlan, D. J., McQuillan, A., Eikelboom, J. W. (2004). Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism: A Meta-Analysis of Randomized, Controlled Trials. ANN INTERN MED 140: 175-183 [Abstract] [Full Text]  
• Baldwin, Z. K., Comerota, A. J., Schwartz, L. B. (2004). Catheter-Directed Thrombolysis for Deep Venous Thrombosis. VASC ENDOVASCULAR SURG 38: 1-9 [Abstract]  
• Goldhaber, S. Z., Elliott, C. G. (2003). Acute Pulmonary Embolism: Part II: Risk Stratification, Treatment, and Prevention. Circulation 108: 2834-2838 [Full Text]  
• Linkins, L.-A., Choi, P. T., Douketis, J. D. (2003). Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism: A Meta-Analysis. ANN INTERN MED 139: 893-900 [Abstract] [Full Text]  
• Raschke, R., Hirsh, J., Guidry, J. R. (2003). Suboptimal Monitoring and Dosing of Unfractionated Heparin in Comparative Studies with Low-Molecular-Weight Heparin. ANN INTERN MED 138: 720-723 [Abstract] [Full Text]  
• Hyers, T. M. (2003). Management of Venous Thromboembolism: Past, Present, and Future. Arch Intern Med 163: 759-768 [Abstract] [Full Text]  
• Lee, Y.-k., Nam, J. H., Shin, H.-C., Byun, Y. (2001). Conjugation of Low-Molecular-Weight Heparin and Deoxycholic Acid for the Development of a New Oral Anticoagulant Agent. Circulation 104: 3116-3120 [Abstract] [Full Text]  
• Stricker, H., Mombelli, G., Pechlaner, C., Gritsch, W., Breddin, H. K., Kakkar, V. V. (2001). Low-Molecular-Weight Heparin in Patients with Deep-Vein Thrombosis. NEJM 345: 292-293 [Full Text]  
• (2001). Low-Molecular-Weight Heparin Effective for DVT. Journal Watch Cardiology 2001: 9-9 [Full Text]